Statins showed no global cognitive harm

Current statin use was not linked to global cognitive impairment in older adults.
*Cross-sectional survey-weighted observational study; Level 4 (OCEBM).

Citation

Ding J, Miao J, Zhang L, Liu Q, Zhang Y, Li J, Li Y. Cognitive safety of statin use in the elderly: Evidence from a nationally representative sample. Journal of Internal Medicine. 2026. doi:10.1111/joim.70159

Background

Statins reduce heart attack and stroke risk, but patients and clinicians remain concerned about possible memory or thinking side effects. This study tested whether current statin use was associated with worse cognition in older United States adults.

Patients

3,137 community-dwelling adults aged 60 years or older from the 2011–2014 National Health and Nutrition Examination Survey. Exclusions included fewer than two cognitive tests or extreme body mass index values.

Intervention

Current statin use, based on prescription medications used in the prior 30 days.

Control

No current statin use.

Outcome

Global cognitive impairment, defined as a composite score more than 1.5 standard deviations below the study mean, using word recall, animal naming, and symbol-substitution tests.

Follow-up Period

None; exposure and cognition were measured at the same survey cycle.

Results

Outcome Adjusted finding
Global cognitive impairment NS
Symbol-substitution impairment OR 0.51 (95% CI 0.31 to 0.85), favoring statin users
Statin intensity and most duration groups NS

OR = odds ratio; CI = confidence interval; NS = not statistically significant.

Results were adjusted for demographics, lifestyle, cardiovascular conditions, depression, multiple medication use, and psychiatric medications. Propensity-weighted and imputed analyses were also neutral. The isolated symbol-substitution finding did not translate into better overall cognition and should be considered hypothesis-generating.

Limitations

Cross-sectional design prevents causal conclusions or long-term safety assessment. Statin exposure was based on recent prescriptions, not adherence or lifetime dose. Residual confounding, healthy-user bias, and selective discontinuation remain possible. Cognitive tests were screening measures, not clinical dementia diagnoses, and institutionalized older adults were not included.

Funding

Chinese governmental/academic grants; authors reported no conflicts.

Clinical Application

Do not withhold indicated statins solely for cognitive concerns; evaluate new symptoms individually and review mood, sleep, and polypharmacy.